Study title: Double blind, double dummy, multinational, multicenter, parallel-group design clinical trial of the efficacy and tolerability of budesonide spray aerosol (200 µg unit dose twice daily) administered via pMDI using the HFA-134a or the CFC propellant in a 12-week treatment period of mild to moderate persistent asthma in pediatric patients. Comparison with an open-label control group treated with budesonide HFA-134a (200 µg unit dose twice daily) given with the ‘JET’ spacer device
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Respiratory Tract Diseases [C08] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: BUDESONIDE | |||||
ATC code: | |||||
Document link: DM-PR-3307-003-03.doc | |||||
Document date: 2015-03-02 | |||||
Study number: DM-PR-3307-003-03 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |